{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:20:40Z","timestamp":1794738040991,"version":"4.9.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The type of cell death has proven to play a crucial role in cancer immunotherapy efficacy. Immunogenic cell death (ICD) enhances tumor adjuvanticity and antigenicity by releasing danger signals and altering the immune peptidome. The immunogenicity of ferroptosis, an iron-dependent form of cell death, remains uncertain. Here, we show that dendritic cell (DC) vaccines loaded with ferroptotic lysates protect mice against glioma growth, inducing IFN-\u03b3 production, and promoting robust CD8\u207a T cell infiltration, activation, and effector memory formation in the tumor microenvironment. The intrinsic immunogenicity of ferroptosis was independent of the glioma type and the ferroptosis inducer. Instead, it critically required the presence of the damage-associated molecular patterns calreticulin and ATP, rather than involving HMGB1\u2013TLR4 signaling. However, supplementing these DAMPs into DC vaccines loaded with non-ICD lysates did not restore efficacy to the level of the ferroptosis-based DC vaccine, suggesting a more complex mechanism beyond a purely DAMP-mediated effect. These findings demonstrate that ferroptosis-loaded DC vaccines elicit a potent, tumor-specific immune response, capable of eradicating intracranial gliomas in mice, which highlights their potential in cancer immunotherapy.<\/jats:p>","DOI":"10.1038\/s41467-026-72737-6","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T14:35:46Z","timestamp":1778164546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-470X","authenticated-orcid":false,"given":"Mariia","family":"Saviuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria D.","family":"Turubanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"De Br\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9767-5386","authenticated-orcid":false,"given":"Sandra","family":"Van Lint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Mendes","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliia","family":"Efimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Braet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-8376","authenticated-orcid":false,"given":"Lore","family":"Van Oudenhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8521-8508","authenticated-orcid":false,"given":"Gitta","family":"Boons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Naessens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7930-8347","authenticated-orcid":false,"given":"Robin","family":"Demuynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Saeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3988-5980","authenticated-orcid":false,"given":"Christian","family":"Vanhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-7574","authenticated-orcid":false,"given":"Lukas","family":"Bunse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3782-0750","authenticated-orcid":false,"given":"Peter M.","family":"van Endert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8939-0169","authenticated-orcid":false,"given":"Robrecht","family":"Raedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9759-6477","authenticated-orcid":false,"given":"Maria V.","family":"Vedunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Krysko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-620X","authenticated-orcid":false,"given":"Roosmarijn E.","family":"Vandenbroucke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6787-8577","authenticated-orcid":false,"given":"Karim","family":"Vermaelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4463-5035","authenticated-orcid":false,"given":"Tatiana A.","family":"Mishchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-3414","authenticated-orcid":false,"given":"Elena","family":"Catanzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-2047","authenticated-orcid":false,"given":"Dmitri V.","family":"Krysko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"72737_CR1","first-page":"381","volume":"71","author":"KD Miller","year":"2021","unstructured":"Miller, K. D. et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J. Clin. 71, 381\u2013406 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"72737_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro. Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro. Oncol."},{"key":"72737_CR3","doi-asserted-by":"crossref","unstructured":"Mishchenko, T. A. et al. Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy. Front. Immunol. 14, 1299064 (2024).","DOI":"10.3389\/fimmu.2023.1299064"},{"key":"72737_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02630-8","volume":"19","author":"CJ Pachocki","year":"2022","unstructured":"Pachocki, C. J. & Hol, E. M. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma. J. Neuroinflamm. 19, 276 (2022).","journal-title":"J. Neuroinflamm."},{"key":"72737_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.radonc.2021.12.019","volume":"167","author":"P Navarria","year":"2022","unstructured":"Navarria, P. et al. Re-irradiation for recurrent high grade glioma (HGG) patients: results of a single arm prospective phase 2 study. Radiother. Oncol. 167, 89\u201396 (2022).","journal-title":"Radiother. Oncol."},{"key":"72737_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"72737_CR7","first-page":"299","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan, A. C. et al. Management of glioblastoma: state of the art and future directions. CA Cancer J. Clin. 70, 299\u2013312 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"72737_CR8","doi-asserted-by":"crossref","unstructured":"Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860\u2013875 (2012).","DOI":"10.1038\/nrc3380"},{"key":"72737_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L., Buqu\u00e9, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97\u2013111 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"72737_CR10","doi-asserted-by":"publisher","first-page":"e000337","DOI":"10.1136\/jitc-2019-000337","volume":"8","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L. et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J. Immunother. Cancer 8, e000337 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"72737_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova, J. et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 11, 1013 (2020).","journal-title":"Cell Death Dis."},{"key":"72737_CR12","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","volume":"202","author":"N Casares","year":"2005","unstructured":"Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691\u20131701 (2005).","journal-title":"J. Exp. Med."},{"key":"72737_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.celrep.2016.03.037","volume":"15","author":"TL Aaes","year":"2016","unstructured":"Aaes, T. L. et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep. 15, 274\u2013287 (2016).","journal-title":"Cell Rep."},{"key":"72737_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1126\/science.aad0395","volume":"350","author":"N Yatim","year":"2015","unstructured":"Yatim, N. et al. RIPK1 and NF-\u03baB signaling in dying cells determines cross-priming of CD8\u2009+\u2009T cells. Science 350, 328\u2013334 (2015).","journal-title":"Science"},{"key":"72737_CR15","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072 (2012).","journal-title":"Cell"},{"key":"72737_CR16","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1080\/15548627.2024.2319901","volume":"20","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. International consensus guidelines for the definition, detection, and interpretation of autophagy-dependent ferroptosis. Autophagy 20, 1213\u20131246 (2024).","journal-title":"Autophagy"},{"key":"72737_CR17","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.cell.2017.09.044","volume":"171","author":"SE Wenzel","year":"2017","unstructured":"Wenzel, S. E. et al. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell 171, 628\u2013641.e26 (2017).","journal-title":"Cell"},{"key":"72737_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41568-019-0149-1","volume":"19","author":"JP Friedmann Angeli","year":"2019","unstructured":"Friedmann Angeli, J. P., Krysko, D. V. & Conrad, M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Cancer 19, 405\u2013414 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"72737_CR19","doi-asserted-by":"publisher","first-page":"e001369","DOI":"10.1136\/jitc-2020-001369","volume":"8","author":"I Efimova","year":"2020","unstructured":"Efimova, I. et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J. Immunother. Cancer 8, e001369 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"72737_CR20","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1080\/15548627.2021.2008692","volume":"18","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. DCN released from ferroptotic cells ignites AGER-dependent immune responses. Autophagy 18, 2036\u20132049 (2022).","journal-title":"Autophagy"},{"key":"72737_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41586-022-05443-0","volume":"612","author":"R Kim","year":"2022","unstructured":"Kim, R. et al. Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature 612, 338\u2013346 (2022).","journal-title":"Nature"},{"key":"72737_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31218-2","volume":"13","author":"B Wiernicki","year":"2022","unstructured":"Wiernicki, B. et al. Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. Nat. Commun. 13, 3676 (2022).","journal-title":"Nat. Commun."},{"key":"72737_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka, K. & Banchereau, J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12, 265\u2013277 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"72737_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau, L. M. et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma. JAMA Oncol. 9, 112 (2023).","journal-title":"JAMA Oncol."},{"key":"72737_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12967-018-1507-6","volume":"16","author":"LM Liau","year":"2018","unstructured":"Liau, L. M. et al. First results on survival from a large Phase 3 clinical trial autologous dendritic cell vaccine newly diagnosed glioblastoma. J. Transl. Med. 16, 142 (2018).","journal-title":"J. Transl. Med."},{"key":"72737_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-107","volume":"12","author":"T Oh","year":"2014","unstructured":"Oh, T. et al. Immunocompetent murine models for the study of glioblastoma immunotherapy. J. Transl. Med. 12, 107 (2014).","journal-title":"J. Transl. Med."},{"key":"72737_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12584-0","volume":"7","author":"J Belmans","year":"2017","unstructured":"Belmans, J. et al. Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival. Sci. Rep. 7, 13902 (2017).","journal-title":"Sci. Rep."},{"key":"72737_CR28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.7150\/jca.4149","volume":"3","author":"E Binello","year":"2012","unstructured":"Binello, E., Qadeer, Z. A., Kothari, H. P., Emdad, L. & Germano, I. M. Stemness of the CT-2A immunocompetent mouse brain tumor model: characterization in vitro. J. Cancer 3, 166\u2013174 (2012).","journal-title":"J. Cancer"},{"key":"72737_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.freeradbiomed.2020.02.027","volume":"152","author":"F Ursini","year":"2020","unstructured":"Ursini, F. & Maiorino, M. Lipid peroxidation and ferroptosis: the role of GSH and GPx4. Free Radic. Biol. Med. 152, 175\u2013185 (2020).","journal-title":"Free Radic. Biol. Med."},{"key":"72737_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-020-00428-9","volume":"6","author":"H Yan","year":"2021","unstructured":"Yan, H. et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct. Target. Ther. 6, 49 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"72737_CR31","doi-asserted-by":"crossref","unstructured":"Garg, A. D. et al. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci. Transl. Med. 8, 105 (2016).","DOI":"10.1126\/scitranslmed.aae0105"},{"key":"72737_CR32","first-page":"1","volume":"48","author":"DSStress Khalsa","year":"2015","unstructured":"Khalsa, D. S. S. tress Meditation, and Alzheimer\u2019s disease. Prev. Where Evid. Stands J. Alzheimer\u2019s. Dis. 48, 1\u201312 (2015).","journal-title":"Prev. Where Evid. Stands J. Alzheimer\u2019s. Dis."},{"key":"72737_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05514-0","volume":"13","author":"M Vedunova","year":"2022","unstructured":"Vedunova, M. et al. DC vaccines loaded with glioma cells killed by photodynamic therapy induce Th17 anti-tumor immunity and provide a four-gene signature for glioma prognosis. Cell Death Dis. 13, 1062 (2022).","journal-title":"Cell Death Dis."},{"key":"72737_CR34","doi-asserted-by":"publisher","unstructured":"Mishchenko, T. A. et al. Gold standard assessment of immunogenic cell death induced by photodynamic therapy: from in vitro to tumor mouse models and anti-cancer vaccination strategies. in (2023). https:\/\/doi.org\/10.1016\/bs.mcb.2023.05.003.","DOI":"10.1016\/bs.mcb.2023.05.003"},{"key":"72737_CR35","doi-asserted-by":"crossref","unstructured":"Turubanova, V. D. et al. Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine. J. Immunother. Cancer 7, 350 (2019).","DOI":"10.1186\/s40425-019-0826-3"},{"key":"72737_CR36","doi-asserted-by":"publisher","first-page":"e2097","DOI":"10.1038\/cddis.2015.411","volume":"7","author":"AD Garg","year":"2016","unstructured":"Garg, A. D., Krysko, D. V., Vandenabeele, P. & Agostinis, P. Extracellular ATP and P2X7 receptor exert context-specific immunogenic effects after immunogenic cancer cell death. Cell Death Dis. 7, e2097\u2013e2097 (2016).","journal-title":"Cell Death Dis."},{"key":"72737_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17704-5","volume":"11","author":"JK Khalsa","year":"2020","unstructured":"Khalsa, J. K. et al. Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types. Nat. Commun. 11, 3912 (2020).","journal-title":"Nat. Commun."},{"key":"72737_CR38","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jcyt.2014.02.017","volume":"16","author":"M Eyrich","year":"2014","unstructured":"Eyrich, M. et al. Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells. Cytotherapy 16, 946\u2013964 (2014).","journal-title":"Cytotherapy"},{"key":"72737_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-15-0163","volume":"4","author":"S Van Lint","year":"2016","unstructured":"Van Lint, S. et al. Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol. Res. 4, 146\u2013156 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"72737_CR40","doi-asserted-by":"crossref","unstructured":"de Mey, W. et al. An mRNA mix redirects dendritic cells towards an antiviral program, inducing anticancer cytotoxic stem cell and central memory CD8\u2009+\u2009T cells. Front. Immunol. 14, 1111523 (2023).","DOI":"10.3389\/fimmu.2023.1111523"},{"key":"72737_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2006.04.007","volume":"106","author":"SJ Wakelin","year":"2006","unstructured":"Wakelin, S. J. et al. \u201cDirty little secrets\u201d\u2014Endotoxin contamination of recombinant proteins. Immunol. Lett. 106, 1\u20137 (2006).","journal-title":"Immunol. Lett."},{"key":"72737_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05072-0","volume":"9","author":"T Duhen","year":"2018","unstructured":"Duhen, T. et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat. Commun. 9, 2724 (2018).","journal-title":"Nat. Commun."},{"key":"72737_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53262-w","volume":"15","author":"K Tanoue","year":"2024","unstructured":"Tanoue, K. et al. Spatial dynamics of CD39\u2009+\u2009CD8+ exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer. Nat. Commun. 15, 9033 (2024).","journal-title":"Nat. Commun."},{"key":"72737_CR44","doi-asserted-by":"crossref","unstructured":"Isaacs, J. F. et al. CD39 is expressed on functional effector and tissue resident memory CD8\u2009+\u2009T cells. J. Immunol. 213, 588\u2013599 (2024).","DOI":"10.4049\/jimmunol.2400151"},{"key":"72737_CR45","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1038\/cddis.2013.156","volume":"4","author":"O Krysko","year":"2013","unstructured":"Krysko, O., L\u00f8ve Aaes, T., Bachert, C., Vandenabeele, P. & Krysko, D. V. Many faces of DAMPs in cancer therapy. Cell Death Dis. 4, e631\u2013e631 (2013).","journal-title":"Cell Death Dis."},{"key":"72737_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04017-6","volume":"21","author":"L Galluzzi","year":"2023","unstructured":"Galluzzi, L., Kepp, O., Hett, E., Kroemer, G. & Marincola, F. M. Immunogenic cell death in cancer: concept and therapeutic implications. J. Transl. Med. 21, 162 (2023).","journal-title":"J. Transl. Med."},{"key":"72737_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51\u201372 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"72737_CR48","doi-asserted-by":"publisher","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","volume":"3","author":"O Kepp","year":"2014","unstructured":"Kepp, O. et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3, e955691 (2014).","journal-title":"Oncoimmunology"},{"key":"72737_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54\u201361 (2007).","journal-title":"Nat. Med."},{"key":"72737_CR50","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh, L. et al. Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050\u20131059 (2007).","journal-title":"Nat. Med."},{"key":"72737_CR51","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1\u03b2\u2013dependent adaptive immunity against tumors. Nat. Med. 15, 1170\u20131178 (2009).","journal-title":"Nat. Med."},{"key":"72737_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/cdd.2013.72","volume":"21","author":"T Yamazaki","year":"2014","unstructured":"Yamazaki, T. et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 21, 69\u201378 (2014).","journal-title":"Cell Death Differ."},{"key":"72737_CR53","first-page":"407","volume":"10","author":"E Catanzaro","year":"2024","unstructured":"Catanzaro, E., Demuynck, R., Naessens, F., Galluzzi, L. & Krysko, D. V. Immunogenicity of ferroptosis in cancer: a matter of context? Trends. Cancer 10, 407\u2013416 (2024).","journal-title":"Cancer"},{"key":"72737_CR54","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi, L., Guilbaud, E., Schmidt, D., Kroemer, G. & Marincola, F. M. Targeting immunogenic cell stress and death for cancer therapy. Nat. Rev. Drug Discov. 23, 445\u2013460 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"72737_CR55","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/s41556-024-01360-8","volume":"26","author":"E Dai","year":"2024","unstructured":"Dai, E. et al. A guideline on the molecular ecosystem regulating ferroptosis. Nat. Cell Biol. 26, 1447\u20131457 (2024).","journal-title":"Nat. Cell Biol."},{"key":"72737_CR56","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/emboj.2009.1","volume":"28","author":"T Panaretakis","year":"2009","unstructured":"Panaretakis, T. et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 28, 578\u2013590 (2009).","journal-title":"EMBO J."},{"key":"72737_CR57","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.bbrc.2019.01.090","volume":"510","author":"Q Wen","year":"2019","unstructured":"Wen, Q., Liu, J., Kang, R., Zhou, B. & Tang, D. The release and activity of HMGB1 in ferroptosis. Biochem. Biophys. Res. Commun. 510, 278\u2013283 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"72737_CR58","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.immuni.2013.02.003","volume":"38","author":"A Kaczmarek","year":"2013","unstructured":"Kaczmarek, A., Vandenabeele, P. & Krysko, D. V. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 38, 209\u2013223 (2013).","journal-title":"Immunity"},{"key":"72737_CR59","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.4161\/onci.21098","volume":"1","author":"J Gamrekelashvili","year":"2012","unstructured":"Gamrekelashvili, J. et al. Primary sterile necrotic cells fail to cross-prime CD8\u2009+\u2009T cells. Oncoimmunology 1, 1017\u20131026 (2012).","journal-title":"Oncoimmunology"},{"key":"72737_CR60","doi-asserted-by":"crossref","unstructured":"Turubanova, V. D. et al. Novel porphyrazine-based photodynamic anti-cancer therapy induces immunogenic cell death. Sci. Rep. 11, 7205 (2021).","DOI":"10.1038\/s41598-021-86354-4"},{"key":"72737_CR61","doi-asserted-by":"publisher","first-page":"e23401","DOI":"10.4161\/onci.23401","volume":"2","author":"S Pellegatta","year":"2013","unstructured":"Pellegatta, S. et al. The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology 2, e23401 (2013).","journal-title":"Oncoimmunology"},{"key":"72737_CR62","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1158\/2326-6066.CIR-24-0333","volume":"13","author":"FS Hodi","year":"2025","unstructured":"Hodi, F. S. et al. First-in-human clinical trial of vaccination with WDVAX, a dendritic cell\u2013activating scaffold incorporating autologous tumor cell lysate, in patients with metastatic melanoma. Cancer Immunol. Res. 13, 978\u2013989 (2025).","journal-title":"Cancer Immunol. Res."},{"key":"72737_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-2659-7","volume":"19","author":"M Rapp","year":"2018","unstructured":"Rapp, M. et al. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Trials 19, 293 (2018).","journal-title":"Trials"},{"key":"72737_CR64","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487\u2013500 (2022).","journal-title":"Nat. Immunol."},{"key":"72737_CR65","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1349-7006.2006.00208.x","volume":"97","author":"T Szatm\u00e1ri","year":"2006","unstructured":"Szatm\u00e1ri, T. et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 97, 546\u2013553 (2006).","journal-title":"Cancer Sci."},{"key":"72737_CR66","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/2021.11.FOCUS21556","volume":"52","author":"V Letchuman","year":"2022","unstructured":"Letchuman, V. et al. Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes. Neurosurg. Focus 52, E5 (2022).","journal-title":"Neurosurg. Focus"},{"key":"72737_CR67","doi-asserted-by":"publisher","first-page":"e009752","DOI":"10.1136\/jitc-2024-009752","volume":"12","author":"C Degavre","year":"2024","unstructured":"Degavre, C. et al. In situ endoscopic photodynamic therapy combined with immature DC vaccination induces a robust T cell response against peritoneal carcinomatosis. J. Immunother. Cancer 12, e009752 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"72737_CR68","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1189\/jlb.0608374","volume":"85","author":"AE Anderson","year":"2009","unstructured":"Anderson, A. E. et al. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J. Leukoc. Biol. 85, 243\u2013250 (2009).","journal-title":"J. Leukoc. Biol."},{"key":"72737_CR69","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00262-006-0245-4","volume":"56","author":"N Leonhartsberger","year":"2007","unstructured":"Leonhartsberger, N. et al. Antigen-independent immune responses after dendritic cell vaccination. Cancer Immunol. Immunother. 56, 897\u2013903 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"72737_CR70","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41418-020-00719-2","volume":"28","author":"X Luo","year":"2021","unstructured":"Luo, X. et al. Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2. Cell Death Differ. 28, 1971\u20131989 (2021).","journal-title":"Cell Death Differ."},{"key":"72737_CR71","doi-asserted-by":"publisher","first-page":"102758","DOI":"10.1016\/j.redox.2023.102758","volume":"63","author":"AA Amoscato","year":"2023","unstructured":"Amoscato, A. A. et al. Formation of protein adducts with Hydroperoxy-PE electrophilic cleavage products during ferroptosis. Redox Biol. 63, 102758 (2023).","journal-title":"Redox Biol."},{"key":"72737_CR72","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1021\/acsomega.0c00080","volume":"5","author":"TM Maia","year":"2020","unstructured":"Maia, T. M. et al. Simple peptide quantification approach for MS-based proteomics quality control. ACS Omega 5, 6754\u20136762 (2020).","journal-title":"ACS Omega"},{"key":"72737_CR73","doi-asserted-by":"publisher","first-page":"e0189209","DOI":"10.1371\/journal.pone.0189209","volume":"13","author":"C Chiva","year":"2018","unstructured":"Chiva, C. et al. QCloud: A cloud-based quality control system for mass spectrometry-based proteomics laboratories. PLoS One 13, e0189209 (2018).","journal-title":"PLoS One"},{"key":"72737_CR74","doi-asserted-by":"publisher","unstructured":"Timmerman, E. & Krysko, D. ProteomeXchange dataset -\u00a0Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy. https:\/\/doi.org\/10.6019\/PXD060116 (2025).","DOI":"10.6019\/PXD060116"},{"key":"72737_CR75","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nprot.2017.147","volume":"13","author":"X Zhang","year":"2018","unstructured":"Zhang, X. et al. Proteome-wide identification of ubiquitin interactions using UbIA-MS. Nat. Protoc. 13, 530\u2013550 (2018).","journal-title":"Nat. Protoc."},{"key":"72737_CR76","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"72737_CR77","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1158\/2326-6066.CIR-19-0464","volume":"8","author":"XM Shao","year":"2020","unstructured":"Shao, X. M. et al. High-throughput prediction of MHC class I and II neoantigens with MHCnuggets. Cancer Immunol. Res. 8, 396\u2013408 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"72737_CR78","doi-asserted-by":"crossref","unstructured":"Pfitzer, L. et al. Accelerating neoantigen discovery: a high-throughput approach to immunogenic target identification. Vaccines 13, 865 (2025).","DOI":"10.3390\/vaccines13080865"},{"key":"72737_CR79","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","volume":"29","author":"A Tesniere","year":"2010","unstructured":"Tesniere, A. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482\u2013491 (2010).","journal-title":"Oncogene"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72737-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72737-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72737-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:03:03Z","timestamp":1783987383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72737-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72737"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72737-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.V.K. and M.S. filed a patent with PCT application WO2025\/003130. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6158"}}